<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04884009</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1701-II-209</org_study_id>
    <nct_id>NCT04884009</nct_id>
  </id_info>
  <brief_title>A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung Cancer</brief_title>
  <official_title>An Open-label, Multicenter PhaseⅡ Study of SHR-1701 in Combination With or Without Famitinib Malate for the Treatment of Extensive Stage Small Cell Lung Cancer After Previous Systemic Chemotherapy Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the efficacy and safety of SHR-1701 in combination&#xD;
      with or without famitinib malate for the treatment of extensive stage small cell lung cancer&#xD;
      after the failure of previous systemic chemotherapy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 31, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>SHR-1701 in combination with or without famitinib</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) based on RECIST 1.1 criteria</measure>
    <time_frame>up to approximately 1 year.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) based on RECIST 1.1 criteria</measure>
    <time_frame>up to approximately 1 year.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) based on RECIST 1.1 criteria</measure>
    <time_frame>up to approximately 1 year.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>up to approximately 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to approximately 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs+ SAEs determined by NCI-CTCAE V5.0</measure>
    <time_frame>Baseline until up to 90 days after end of treatment.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>SHR-1701+ Famitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR-1701</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1701； Famitinib</intervention_name>
    <description>SHR-1701+ Famitinib</description>
    <arm_group_label>SHR-1701+ Famitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1701</intervention_name>
    <description>SHR-1701</description>
    <arm_group_label>SHR-1701</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients voluntarily participated in the clinical study, understood the study&#xD;
             procedures and are able to sign the informed consent form.&#xD;
&#xD;
          2. 18 to 75 years old, male or female.&#xD;
&#xD;
          3. Histologically or cytologically confirmed extensive stage small cell lung&#xD;
             cancer（ED-SCLC）.&#xD;
&#xD;
          4. ECOG Performance Status of 0 or 1.&#xD;
&#xD;
          5. Adequate hematological, hepatic and renal function.&#xD;
&#xD;
          6. Female subjects of child-bearing potential must have a negative serum HCG test before&#xD;
             treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed mixed SCLC and NSCLC.&#xD;
&#xD;
          2. Untreated central nervous system metastases.&#xD;
&#xD;
          3. Cancerous meningitis (meningeal metastasis).&#xD;
&#xD;
          4. Uncontrolled pleural effusion, pericardial effusion or ascites.&#xD;
&#xD;
          5. Tumor infiltration into the great vessels on imaging;&#xD;
&#xD;
          6. Hemoptysis symptoms and maximum daily hemoptysis ≥ 2.5ml occurred within 1 month.&#xD;
&#xD;
          7. Uncontrolled tumor-related pain.&#xD;
&#xD;
          8. Malignancies other than SCLC within 5 years.&#xD;
&#xD;
          9. Systemic antitumor therapy was received 4 weeks prior to trial treatment.&#xD;
&#xD;
         10. History of autoimmune diseases.&#xD;
&#xD;
         11. Significant cardiovascular disease.&#xD;
&#xD;
         12. Inadequately controlled hypertension.&#xD;
&#xD;
         13. Known history of testing positive test for HIV or known AIDS.&#xD;
&#xD;
         14. Patients with active hepatitis B or hepatitis C&#xD;
&#xD;
         15. Severe infections within 4 weeks prior to trial treatment.&#xD;
&#xD;
         16. Active tuberculosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wei Shi</last_name>
    <phone>021-68868570</phone>
    <email>wei.shi@hengrui.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Huan Li</last_name>
    <phone>17721286513</phone>
    <email>huan.li@hengrui.com</email>
  </overall_contact_backup>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 7, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

